4-Antibody AG Forms Collaboration with Human Genome Sciences

BASEL, Switzerland--(BUSINESS WIRE)-- 4-Antibody AG today announced the signing of a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies. Financial terms of the deal were not disclosed.

The collaboration with HGS is focused on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid discovery of fully human antibodies against novel targets nominated by HGS. The Retrocyte Display® technology (Retroviral B lymphocyte Display) is a potent and fast tool for high quality therapeutic antibody discovery and optimization using a rapid flow cytometry approach. Full-length immunoglobulin antibody libraries are expressed in mammalian B-lineage cells, the cell designed by nature for optimal antibody display, resulting in ‘better-behaved’, fully human antibodies. This collaboration agreement, which initially involves two projects, is 4-Antibody’s second such alliance with a pharmaceutical partner, the first being with Boehringer Ingelheim which commenced in early 2010.

Dr Robert Burns, 4-Antibody’s CEO, said: “We’re delighted to announce our second collaboration with an established pharmaceutical partner. Collaborations serve an important role in validating our Retrocyte Display® technology platform and we’re delighted that HGS wanted to enter into this multi-target collaboration with us. This adds an additional momentum to our other ongoing partnering activities.”

About 4-Antibody AG

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. The Company’s lead development product is an anti-cytomegalovirus antibody drug. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany.

For more information please visit: www.4-antibody.com

*** 4-Antibody moves to new offices and labs***

Please note the new address and phone number of our Basel operation:

4-Antibody AG
Hochbergerstrasse 60C
CH-4057 Basel, Switzerland
Phone: +41-61-633-20-60

About Human Genome Sciences

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease. For more information about HGS, please visit the Company’s web site at www.hgsi.com .



CONTACT:

4-Antibody AG
Dr Robert Burns, CEO
t: +41-61-633-20-60
e: [email protected]
or
College Hill
Dr Robert Mayer
Account Manager
t: +49-89-5238-8030
e: [email protected]

KEYWORDS:   Europe  Germany  Switzerland

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.